Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

PLoS Medicine

Volumn 2, Issue 11, 2005, Pages 1167-1176

  Greulich, Heidi ^a,b,c   Chen, Tzu Hsiu ^a,c   Feng, Whei ^a,c   Jänne, Pasi A ^a,b   Alvarez, James V ^a,b   Zappaterra, Mauro ^a   Bulmer, Sara E ^a   Frank, David A ^a,b   Hahn, William C ^a,b,c,d   Sellers, William R ^a,b,c   Meyerson, Matthew ^a,b,d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CL 387785; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; N [4 (3 BROMOANILINO) 6 QUINAZOLINYL] 2 BUTYNAMIDE; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; PROTEIN SHC; QUINAZOLINE DERIVATIVE; SHC1 PROTEIN, HUMAN; SHC1 PROTEIN, MOUSE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; STAT3 PROTEIN;

ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVATION; EXON; FIBROBLAST; GENE INSERTION; GENE MUTATION; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; ONCOGENE; PHOSPHORYLATION; ANIMAL; BIOSYNTHESIS; CELL STRAIN 3T3; CELL TRANSFORMATION; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG RESISTANCE; DRUG SCREENING; EXPERIMENTAL NEOPLASM; GENE THERAPY; GENETIC TRANSFECTION; GENETICS; METABOLISM; MOUSE; MUTATION; NUDE MOUSE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; EXONS; GENETIC THERAPY; HUMANS; MICE; MICE, NUDE; MUTATION; NEOPLASMS, EXPERIMENTAL; NIH 3T3 CELLS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SHC SIGNALING ADAPTOR PROTEINS; STAT3 TRANSCRIPTION FACTOR; TRANSFECTION; TUMOR STEM CELL ASSAY;

EID: 28444478439     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0020313     Document Type: Article

References (35)

1. Olayioye MA, Neve RM, Lane HA, Hynes NE (2000) The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J 19: 3159-3167.
2. Yarden Y (2001) The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer 37: S3-8.
3. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, et al. (2003) Epidermal growth factor receptor: Mechanisms of activation and signalling. Exp Cell Res 284: 31-53.
4. Gamett DC, Tracy SE, Robinson HL (1986) Differences in sequences encoding the carboxyl-terminal domain of the epidermal growth factor receptor correlate with differences in the disease potential of viral erbB genes. Proc Natl Acad Sci U S A 83: 6053-6057.
5. Boerner JL, Danielsen A, Maihle NJ (2003) Ligand-independent oncogenic signaling by the epidermal growth factor receptor: v-ErbB as a paradigm. Exp Cell Res 284: 111-121.
6. Garcia de Palazzo IE, Adams GP, Sundareshan P, Wong AJ, Testa JR, et al. (1993) Expression of mutated epidermal growth factor receptor by nonsmall cell lung carcinomas. Cancer Res 53: 3217-3220.
7. Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, et al. (1995) Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 55: 5536-5539.
8. Velu TJ, Beguinot L, Vass WC, Willingham MC, Merlino GT, et al. (1987) Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene. Science 238: 1408-1410.
9. Danielsen AJ, Maihle NJ (2002) Ligand-independent oncogenic transformation by the EGF receptor requires kinase domain catalytic activity. Exp Cell Res 275: 9-16.
10. Huang HS, Nagane M, Klingbeil CK, Lin H, Nishikawa R, et al. (1997) The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 272: 2927-2935.
11. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
12. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
13. Pao W, Miller V, Zakowski M, Doherty J, Politi K, et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101: 13306-13311.
14. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, et al. (2004) Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications. Cancer Res 64: 8919-8923.
15. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, et al. (2005) Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23: 2513-2520.
16. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, et al. (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97: 339-346.
17. Chou TY, Chiu CH, Li LH, Hsiao CY, Tzen CY, et al. (2005) Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 11: 3750-3757.
18. Huang SF, Liu HP, Li LH, Ku YC, Fu YN, et al. (2004) High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10: 8195-8203.
19. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792.
20. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73.
21. Tracy S, Mukohara T, Hansen M, Meyerson M, Johnson BE, et al. (2004) Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res 64: 7241-7244.
22. Sordella R, Bell DW, Haber DA, Settleman J (2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163-1167.
23. Lundberg AS, Randell SH, Stewart SA, Elenbaas B, Hartwell KA, et al. (2002) Immortalization and transformation of primary human airway epithelial cells by gene transfer. Oncogene 21: 4577-4586.
24. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, et al. (1999) Creation of human tumour cells with defined genetic elements. Nature 400: 464-468.
25. Besser D, Bromberg JF, Darnell JE Jr, Hanafusa H (1999) A single amino acid substitution in the v-Eyk intracellular domain results in activation of Stat3 and enhances cellular transformation. Mol Cell Biol 19: 1401-1409.
26. Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, et al. (1999) Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell 4: 1029-1040.
27. Amann J, Kalyankrishna S, Massion PP, Ohm JE, Girard L, et al. (2005) Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 65: 226-235.
28. Okabayashi Y, Kido Y, Okutani T, Sugimoto Y, Sakaguchi K, et al. (1994) Tyrosines 1148 and 1173 of activated human epidermal growth factor receptors are binding sites of Shc in intact cells. J Biol Chem 269: 18674-18678.
29. Pelicci G, Lanfrancone L, Grignani F, McGlade J, Cavallo F, et al. (1992) A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell 70: 93-104.
30. Zhong Z, Wen Z, Darnell JE Jr (1994) Stat3: A STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264: 95-98.
31. Rodrigues GA, Falasca M, Zhang Z, Ong SH, Schlessinger J (2000) A novel positive feedback loop mediated by the docking protein Gab1 and phosphatidylinositol 3-kinase in epidermal growth factor receptor signaling. Mol Cell Biol 20: 1448-1459.
32. Jiang J, Greulich G, Sellers WR, Meyerson M, Grif.n J (2005) EGFindependent transformation of Ba/F3 cells with cancer-derived EGFR mutants induces gefitinib-sensitive cell cycle progression. Cancer Res. In Press.
33. Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn WD Jr, et al. (2004) United States Food and Drug Administration Drug approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 10: 1212-1218.
34. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, et al. (2001) Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19: 3267-3279.
35. Discafani CM, Carroll ML, Floyd MB Jr, Hollander IJ, Husain Z, et al. (1999) Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2- butynamide (CL-387,785). Biochem Pharmacol 57: 917-925.